Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a report issued on Tuesday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 1.7 %

Brooklyn ImmunoTherapeutics stock traded down $0.03 during mid-day trading on Tuesday, reaching $1.76. The company had a trading volume of 2,368 shares, compared to its average volume of 515,543. The company has a 50 day moving average of $1.60 and a 200-day moving average of $1.97. The firm has a market cap of $103.54 million, a price-to-earnings ratio of -0.78 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10.

Institutional Investors Weigh In On Brooklyn ImmunoTherapeutics

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Brooklyn ImmunoTherapeutics Inc (NYSE:BTX – Free Report) by 20.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,459,626 shares of the company’s stock after buying an additional 243,826 shares during the period. Renaissance Technologies LLC owned 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent quarter. 26.00% of the stock is currently owned by hedge funds and other institutional investors.

About Brooklyn ImmunoTherapeutics

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Read More